Cargando…

Drug addiction: from bench to bedside

Drug addiction is responsible for millions of deaths per year around the world. Still, its management as a chronic disease is shadowed by misconceptions from the general public. Indeed, drug consumers are often labelled as “weak”, “immoral” or “depraved”. Consequently, drug addiction is often percei...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheron, Julian, Kerchove d’Exaerde, Alban de
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361217/
https://www.ncbi.nlm.nih.gov/pubmed/34385417
http://dx.doi.org/10.1038/s41398-021-01542-0
_version_ 1783737916425502720
author Cheron, Julian
Kerchove d’Exaerde, Alban de
author_facet Cheron, Julian
Kerchove d’Exaerde, Alban de
author_sort Cheron, Julian
collection PubMed
description Drug addiction is responsible for millions of deaths per year around the world. Still, its management as a chronic disease is shadowed by misconceptions from the general public. Indeed, drug consumers are often labelled as “weak”, “immoral” or “depraved”. Consequently, drug addiction is often perceived as an individual problem and not societal. In technical terms, drug addiction is defined as a chronic, relapsing disease resulting from sustained effects of drugs on the brain. Through a better characterisation of the cerebral circuits involved, and the long-term modifications of the brain induced by addictive drugs administrations, first, we might be able to change the way the general public see the patient who is suffering from drug addiction, and second, we might be able to find new treatments to normalise the altered brain homeostasis. In this review, we synthetise the contribution of fundamental research to the understanding drug addiction and its contribution to potential novel therapeutics. Mostly based on drug-induced modifications of synaptic plasticity and epigenetic mechanisms (and their behavioural correlates) and after demonstration of their reversibility, we tried to highlight promising therapeutics. We also underline the specific temporal dynamics and psychosocial aspects of this complex psychiatric disease adding parameters to be considered in clinical trials and paving the way to test new therapeutic venues.
format Online
Article
Text
id pubmed-8361217
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83612172021-08-19 Drug addiction: from bench to bedside Cheron, Julian Kerchove d’Exaerde, Alban de Transl Psychiatry Review Article Drug addiction is responsible for millions of deaths per year around the world. Still, its management as a chronic disease is shadowed by misconceptions from the general public. Indeed, drug consumers are often labelled as “weak”, “immoral” or “depraved”. Consequently, drug addiction is often perceived as an individual problem and not societal. In technical terms, drug addiction is defined as a chronic, relapsing disease resulting from sustained effects of drugs on the brain. Through a better characterisation of the cerebral circuits involved, and the long-term modifications of the brain induced by addictive drugs administrations, first, we might be able to change the way the general public see the patient who is suffering from drug addiction, and second, we might be able to find new treatments to normalise the altered brain homeostasis. In this review, we synthetise the contribution of fundamental research to the understanding drug addiction and its contribution to potential novel therapeutics. Mostly based on drug-induced modifications of synaptic plasticity and epigenetic mechanisms (and their behavioural correlates) and after demonstration of their reversibility, we tried to highlight promising therapeutics. We also underline the specific temporal dynamics and psychosocial aspects of this complex psychiatric disease adding parameters to be considered in clinical trials and paving the way to test new therapeutic venues. Nature Publishing Group UK 2021-08-12 /pmc/articles/PMC8361217/ /pubmed/34385417 http://dx.doi.org/10.1038/s41398-021-01542-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Cheron, Julian
Kerchove d’Exaerde, Alban de
Drug addiction: from bench to bedside
title Drug addiction: from bench to bedside
title_full Drug addiction: from bench to bedside
title_fullStr Drug addiction: from bench to bedside
title_full_unstemmed Drug addiction: from bench to bedside
title_short Drug addiction: from bench to bedside
title_sort drug addiction: from bench to bedside
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361217/
https://www.ncbi.nlm.nih.gov/pubmed/34385417
http://dx.doi.org/10.1038/s41398-021-01542-0
work_keys_str_mv AT cheronjulian drugaddictionfrombenchtobedside
AT kerchovedexaerdealbande drugaddictionfrombenchtobedside